KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Current Liabilities: 2011-2025

Historic Total Current Liabilities for Sarepta Therapeutics (SRPT) over the last 14 years, with Sep 2025 value amounting to $921.4 million.

  • Sarepta Therapeutics' Total Current Liabilities rose 31.73% to $921.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $921.4 million, marking a year-over-year increase of 31.73%. This contributed to the annual value of $731.7 million for FY2024, which is 11.94% up from last year.
  • Sarepta Therapeutics' Total Current Liabilities amounted to $921.4 million in Q3 2025, which was up 0.16% from $919.9 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Total Current Liabilities peaked at $921.4 million during Q3 2025, and registered a low of $364.7 million during Q1 2021.
  • In the last 3 years, Sarepta Therapeutics' Total Current Liabilities had a median value of $653.7 million in 2023 and averaged $665.0 million.
  • In the last 5 years, Sarepta Therapeutics' Total Current Liabilities surged by 61.45% in 2022 and then declined by 25.24% in 2023.
  • Over the past 5 years, Sarepta Therapeutics' Total Current Liabilities (Quarterly) stood at $452.7 million in 2021, then soared by 36.86% to $619.6 million in 2022, then rose by 5.50% to $653.7 million in 2023, then rose by 11.94% to $731.7 million in 2024, then soared by 31.73% to $921.4 million in 2025.
  • Its Total Current Liabilities was $921.4 million in Q3 2025, compared to $919.9 million in Q2 2025 and $605.6 million in Q1 2025.